GSK has revised its annual vaccine sales forecast following new guidance on RSV from the CDC. But new evidence offers new ...
If approved, the co-administration of Arexvy and Shingrix could provide a more convenient vaccination regimen for patients ...
UK drugmaker GSK presented positive Phase III trial data at the European Geriatric Medicine Society Congress. The trial ...
GSK (GSK) reached the main goal in a Phase 3 trial for its RSV shot, Arexvy co--administered with Shingles vaccine Shingrix.
Findings showed a noninferior immune response for both vaccines when Shingrix and Arexvy were coadministered compared with separate administration (primary endpoint). Both anti-gE antibody ...
GSK touts co-administration data for RSV, shingles vaccines as narrowed CDC guidance threatens sales
In the study, co-administration of GSK's RSV vaccine Arexvy and shingles shot Shingrix elicited non-inferior immune responses ...
GSK plc (NYSE:GSK) released topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, ...
British drugmaker GSK said on Wednesday its respiratory syncytial virus (RSV) vaccine, when given together with its shingles ...
Co-administration of the RSV and shingles adjuvanted vaccines was well tolerated, with acceptable reactogenicity and safety ...
PHN is characterised by pain lasting from three months to several years after the rash subsides, and it is also the most ...
The risk for incident gout following RZV exposure was not increased among adults aged 50 years or older, according to study findings.
GSK has launched it's Shingles vaccine in Malaysia and here's all you need to know about it. From what it is, to the side ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback